FDA Cracks Down on GLP-1 Compounding: 30 Warning Letters and DOJ Referrals
Summary
On February 6, 2026, the FDA announced its intent to restrict GLP-1 APIs used in non-FDA-approved compounded drugs mass-marketed as alternatives to Wegovy and Ozempic, sending 30 warning letters to telehealth companies making false or misleading claims. Hims & Hers launched compounded oral semaglutide on February 5, was referred to DOJ on February 6, and pulled the product by February 7. Safety reports include dosing errors, hospitalizations, and fraudulent products in the compounded GLP-1 market.
Key Changes
- 30 warning letters sent to telehealth companies for GLP-1 marketing claims
- DOJ referrals for non-compliant compounded GLP-1 products
- GLP-1 API restrictions for non-FDA-approved compounding
- Enhanced safety monitoring for compounded semaglutide and tirzepatide
Affected Industries
Source
Key Dates
Related Regulations
SEC Launches Project Crypto Initiative for Digital Asset Framework
SEC · Jul 31, 2025
SEC Permits In-Kind Redemptions for Crypto Asset ETPs
SEC · Jul 29, 2025
SEC Issues Guidance on Crypto Asset Custody by Broker-Dealers
SEC · Dec 17, 2025
SEC Clarifies Liquid Staking Activities Not Securities
SEC · Aug 5, 2025
FDA Approves Suzetrigine (Journavx) - First New Acute Pain Drug in 20 Years
FDA · Jan 30, 2025